Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Min-Sang, Cho, Hee Jin, Hong, Jung Yong, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Cho, Yong Beom, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649869/
https://www.ncbi.nlm.nih.gov/pubmed/33224274
http://dx.doi.org/10.1177/1758835920965842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649869/
https://www.ncbi.nlm.nih.gov/pubmed/33224274
http://dx.doi.org/10.1177/1758835920965842

Ejemplares similares